Citadel Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15M | Buy |
1,954,100
+1,327,900
| +212% | +$9.09M | ﹤0.01% | 2687 |
|
|
2025
Q4 | $1.24M | Buy |
626,200
+125,700
| +25% | +$285K | ﹤0.01% | 6929 |
|
|
2025
Q3 | $1.23M | Buy |
500,500
+84,900
| +20% | +$219K | ﹤0.01% | 7094 |
|
|
2025
Q2 | $1.1M | Sell |
415,600
-67,500
| -14% | -$182K | ﹤0.01% | 6892 |
|
|
2025
Q1 | $1.45M | Sell |
483,100
-242,200
| -33% | -$734K | ﹤0.01% | 6150 |
|
|
2024
Q4 | $1.86M | Buy |
725,300
+220,600
| +44% | +$919K | ﹤0.01% | 5780 |
|
|
2024
Q3 | $1.88M | Sell |
504,700
-3,800
| -0.7% | -$17.6K | ﹤0.01% | 5656 |
|
|
2024
Q2 | $3.21M | Sell |
508,500
-8,400
| -2% | -$55.4K | ﹤0.01% | 4463 |
|
|
2024
Q1 | $2.78M | Buy |
516,900
+160,000
| +45% | +$725K | ﹤0.01% | 4918 |
|
|
2023
Q4 | $1.79M | Buy |
356,900
+101,100
| +40% | +$317K | ﹤0.01% | 5560 |
|
|
2023
Q3 | $432K | Buy |
255,800
+46,400
| +22% | +$93.2K | ﹤0.01% | 8388 |
|
|
2023
Q2 | $582K | Buy |
209,400
+124,900
| +148% | +$353K | ﹤0.01% | 7610 |
|
|
2023
Q1 | $154K | Buy |
84,500
+6,000
| +8% | +$18.7K | ﹤0.01% | 10598 |
|
|
2022
Q4 | $398K | Buy |
78,500
+1,200
| +2% | +$6.59K | ﹤0.01% | 8727 |
|
|
2022
Q3 | $384K | Buy |
77,300
+5,200
| +7% | +$23.7K | ﹤0.01% | 9032 |
|
|
2022
Q2 | $268K | Sell |
72,100
-21,200
| -23% | -$85.2K | ﹤0.01% | 10061 |
|
|
2022
Q1 | $523K | Sell |
93,300
-121,500
| -57% | -$745K | ﹤0.01% | 9281 |
|
|
2021
Q4 | $1.31M | Sell |
214,800
-31,300
| -13% | -$235K | ﹤0.01% | 7241 |
|
|
2021
Q3 | $2.4M | Buy |
246,100
+4,700
| +2% | +$51.7K | ﹤0.01% | 5903 |
|
|
2021
Q2 | $3.45M | Sell |
241,400
-28,300
| -10% | -$468K | ﹤0.01% | 5274 |
|
|
2021
Q1 | $6.4M | Buy |
269,700
+88,000
| +48% | +$2.28M | ﹤0.01% | 3758 |
|
|
2020
Q4 | $2.42M | Buy |
181,700
+153,200
| +538% | +$1.47M | ﹤0.01% | 4958 |
|
|
2020
Q3 | $198K | Sell |
28,500
-5,700
| -17% | -$56.8K | ﹤0.01% | 8806 |
|
|
2020
Q2 | $420K | Buy |
+34,200
| New | +$193K | ﹤0.01% | 7365 |
|
|
2019
Q3 | – | Sell |
-23,300
| Closed | -$24K | – | 9431 |
|
|
2019
Q2 | $24K | Buy |
23,300
+11,100
| +91% | +$12.8K | ﹤0.01% | 8915 |
|
|
2019
Q1 | $19K | Buy |
+12,200
| New | +$15.3K | ﹤0.01% | 9071 |
|
|
2016
Q3 | – | Sell |
-12,100
| Closed | -$75K | – | 7433 |
|
|
2016
Q2 | $75K | Buy |
+12,100
| New | +$93.9K | ﹤0.01% | 6301 |
|
|
2016
Q1 | – | Sell |
-2,200
| Closed | -$38K | – | 7297 |
|
|
2015
Q4 | $38K | Sell |
2,200
-600
| -21% | -$8.9K | ﹤0.01% | 7509 |
|
|
2015
Q3 | $32K | Buy |
+2,800
| New | +$61.1K | ﹤0.01% | 7877 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Citadel Advisors's IBRX Position: Q1 2026 in Review
Citadel Advisors reduced its ImmunityBio (IBRX) stake by 57% in Q1 2026, selling an estimated $2.73M and leaving 305,578 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5752.
Citadel Advisors first reported a position in IBRX in Q3 2015 and has held it in 30 quarters since. The position peaked at $6.27M in Q2 2020. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Citadel Advisors held 305,578 shares of ImmunityBio worth $2.34M as of Q1 2026.
- Citadel Advisors sold 398,996 ImmunityBio shares in Q1 2026, an estimated $2.73M.
- ImmunityBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5752 holding.
- Citadel Advisors first reported a position in ImmunityBio in Q3 2015 and has held it in 30 quarters since.
- Citadel Advisors's ImmunityBio position peaked at $6.27M in Q2 2020.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.